Annals of Surgical Oncology

, Volume 11, Supplement 3, pp 208S–210S

NSABP-32: Phase III, randomized trial comparing axillary resection with sentinal lymph node dissection: A description of the trial

Authors

    • Department of Surgery, College of MedicineUniversity of Vermont
  • Thomas B. Julian
    • National Surgical Breast and Bowel Project
  • Seth P. Harlow
    • Department of Surgery, College of MedicineUniversity of Vermont
  • Donald L. Weaver
    • Department of Pathology and Medical Statistics, College of MedicineUniversity of Vermont
  • Taka Ashikaga
    • National Surgical Breast and Bowel Project
  • John Bryant
    • Uiversity of Pittsburgh
  • Richard M. Single
    • Department of Pathology and Medical Statistics, College of MedicineUniversity of Vermont
  • Norman Wolmark
    • National Surgical Breast and Bowel Project
Article

DOI: 10.1007/BF02523630

Cite this article as:
Krag, D.N., Julian, T.B., Harlow, S.P. et al. Annals of Surgical Oncology (2004) 11: 208S. doi:10.1007/BF02523630

Abstract

The NSABP-32 trial is a randomized, phase III clinical trial to compare sentinel node (SN) resection to conventional axillary dissection in clinically node-negative breast cancer patients. The primary aims of the trial are to determine if removal of only SNs provides survival and regional control equivalent to those of axillary dissection, while diminishing the magnitude of surgically related side effects. In order to ensure consistency of the outcomes for this trial, a standardized method of SN surgery has been utilized for all cases. A secondary aim of the B32 trial is to evaluate whether patients with “occult” metastases in the SNs have worse survival. Accrual is taking place at 73 institutions in North America, and 217 surgeons are enrolling patients.

Key Words

Breast cancer Clinical trial Sentinel node Survival

Copyright information

© The Society of Surgical Oncology, Inc. 2004